Yong‐Sung Kim

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Mi Kwon Son · 3 shared papers, 2018–2022 · strength 0.31
   • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
2. Jung Hee Park · 3 shared papers, 2018–2022 · strength 0.31
   • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
3. Zhenghuan Fang · 3 shared papers, 2018–2022 · strength 0.31
   • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
4. Hong Hua Yan · 3 shared papers, 2018–2022 · strength 0.31
   • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
5. Kyung Hee Jung · 3 shared papers, 2018–2022 · strength 0.31
   • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
6. Yeo Wool Kang · 3 shared papers, 2018–2022 · strength 0.31
   • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
7. Soon‐Sun Hong · 3 shared papers, 2018–2022 · strength 0.31
   • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
8. Seul Lee · 1 shared paper, 2026 · strength 0.30
   • Paper Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancrea… DOI 10.1186/s13036-026-00651-y↗
9. Ji Eun Lee · 2 shared papers, 2018–2021 · strength 0.17
   • Paper Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing e… DOI 10.1016/j.canlet.2021.03.015↗
   • Paper KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. DOI 10.1016/j.canlet.2018.09.013↗
10. Ji Eun Lee · 1 shared paper, 2022 · strength 0.14
    • Paper Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. DOI 10.4062/biomolther.2021.145↗
11. YJ Kim · 1 shared paper, 2017 · strength 0.09
    • Paper Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with i… DOI 10.1038/onc.2016.407↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.